Clinical Research Center

Rediff.com » News » Clinical Research Center

News for Clinical Research Center

News
Business
Sports

'Omicron is a very, very obvious case for boosters'

'An individual who maybe has had two vaccines, or has had two vaccines, and a booster, is going to be pretty well protected.' IMAGE: A municipal corporation worker administers a dose of COVID-19......

Covaxin's 50 pc efficacy adequate for Covid, say experts

The decline in the effectiveness of Covaxin, India's indigenous COVID-19 vaccine, from 77.8 per cent to 50 per cent during a Delta-driven case surge in April and May this year is neither bad nor......

Covaxin safe, shows 77.8% efficacy against symptomatic Covid: Lancet

Two doses of Covaxin, India's indigenous COVID-19 vaccine, offer 77.8 per cent protection against symptomatic disease and present no serious safety concerns, according to an interim analysis of its......

Mix-and-match vaccines highly effective against Covid: Study

People who received a first dose of the Oxford-AstraZeneca COVID-19 vaccine followed by an mRNA vaccine shot had a lower risk of infection compared to those immunised with both doses of the......

Explained: What USFDA full approval to Pfizer-BioNTech vaccine means

Pfizer can show the FDA approval to the Indian regulator and present a case that based on whatever data submitted, the US regulator has granted a full marketing nod, says Sohini Das. IMAGE: Vials......

Serum Institute to provide Covid vaccine at Rs 250 a dose

Serum Institute of India plans to make 300 million doses of AZD1222 by December, and will begin phase-2 trials soon. It has also tied up with Novavax for development and commercialisation of its......

'We will price Covid vaccine below Rs 1,000'

'Once the trials are successful in India and the UK, we are certain that COVISHIELD will be one of the first vaccines to be introduced.' IMAGE: The Reference Center for Special Immunobiologicals......

As OPD footfalls drop, private hospitals battle for survival

Private hospitals, especially smaller standalone ones, are staring at a crisis that they were not prepared for. Analysts say larger corporate chains have to brace up for at least six months for......

How IITs are gearing up to fight COVID-19 menace

While some researchers are developing prototypes for ventilators to overcome their shortage, others have teamed up to develop testing kits. IITs across the country have joined the fight against......

Cancer drug prices highest in US, treatment expensive in India

The lowest drug prices were found in India and South Africa. But after calculating price as a percentage of wealth adjusted for the cost of living, cancer drugs appeared to be least......

Can Serena make tennis comeback after childbirth?

It would be perfectly safe for Serena Williams to continue with rigorous training throughout pregnancy, but how quickly the 35-year-old would return to tournament tennis is uncertain. IMAGE:......

Why the Zika virus is causing alarm

Global health officials are racing to better understand the Zika virus behind a major outbreak that began in Brazil last year and has spread to many countries in the Americas. IMAGE: Rio 2016......

Rediff News